Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: A Retrospective Monoinstitutional Study
Affiliations
- PMID: 32627130
- DOI: 10.1007/s12029-020-00452-6
Abstract
Background and aims: The prognostic role of family history of cancer (FHC) in resected colorectal cancer (CRC) is controversial. The aim of the current study was to evaluate its impact in a monoinstitutional series of stage III CRC patients.
Methods: This single institution retrospective analysis is aimed at evaluating whether FHC affects overall survival (OS) and disease-free survival (DFS) in stage III CRC patients. Moreover, the role of both colorectal FHC (FHCRC, in patients with at least one relative with CRC) and FHC "burden" have been investigated; patients were classified according to FHC in FHC negative, FHC-low (one "familial cluster" among parents/children/grandparents, brothers/sisters, uncles/cousins), and FHC-high (at least two clusters of those above mentioned).
Results: From October 2000 to March 2019, 112 consecutive stage III CRC patients have been evaluated. Median age was 67 years (range 24-89); male/female ratio was 64/48. Fifty-three (47.3%) patients were FHC-negative while 59 (52.7%) patients were FHC-positive, 18 (16.1%) of whom were FHCRC-positive. Thirty-three (29.5%) patients were FHC-low, and 10 (8.9%) were FHC-high. At a median follow-up of 41.9 months, no statistically significant differences in DFS were found. FHC-positive patients had a significantly longer OS than FHC-negative (HR = 0.32 [95% CI 0.12-0.84], p = 0.0210), and a significant trend towards improved OS according to the FHC burden was found (p = 0.0255). No statistically significant differences were found in DFS and OS according to FHCRC.
Conclusion: In this retrospective analysis, FHC-positive stage III CRC patients had a significantly longer OS compared to FHC-negative. Moreover, this survival benefit seems to increase according to the FHC burden. Further prospective studies, with longer follow-up and larger sample size, are necessary to confirm FHC as prognostic factor in this setting.
Keywords: CRC; FHC; Familiarity; Prognostic factors.
Similar articles
- Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.Ann Oncol. 2015 Mar;26(3):535-41. doi: 10.1093/annonc/mdu568. Epub 2014 Dec 15.PMID: 25515656 Clinical Trial.
- Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study.Oncoimmunology. 2020 Jan 7;9(1):1710389. doi: 10.1080/2162402X.2019.1710389. eCollection 2020.PMID: 32002308 Free PMC article.
- Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients.BMC Cancer. 2018 Dec 3;18(1):1202. doi: 10.1186/s12885-018-5042-x.PMID: 30509242 Free PMC article.
- Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.Clin Genet. 2020 Jan;97(1):25-38. doi: 10.1111/cge.13628. Epub 2019 Sep 4.PMID: 31432497 Review.
- Prognostic value of perineural invasion in colorectal cancer: a meta-analysis.J Gastrointest Surg. 2015 Jun;19(6):1113-22. doi: 10.1007/s11605-015-2761-z. Epub 2015 Feb 7.PMID: 25663635 Review.
No hay comentarios:
Publicar un comentario